Biogen Inc (BIIB.xnas) is a multinational biotechnology company and pioneers in neuroscience headquartered in Massachusetts, America. Biogen specialises in the discovery, development, and delivery of therapies to treat neurological diseases to patients globally with marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA, FUMADERM and SPINRAZA. Biogen is the first company that FDA approved Biogen’s Alzheimer’s disease drug aducanumab, which U.S. regulators cleared to slow cognitive decline in people living with the disease. Biogen is one of the world’s first global biotechnology companies aiming the last decade to defeat devastating neurological diseases with 38 office locations across 33 countries. The company operates outside of the United States, across Europe, Canada, Latin America, the Middle East and the Asia Pacific and employs 9.100 people. Biogen has a network of distribution partners in over 50 additional countries with 42 subsidiaries and a $13.4B (USD) in 2020 yearly revenue. The Biogen Inc stock (BIIB.xnas) is traded on the NASDAQ and has a market capitalisation of $32.92B (USD) as of December 2021. The U.S regulators approved Biogen’s aducanumab drug to treat Alzheimer in June 2021 with the price of $56,000 (USD) per year.
Biogen Inc (BIIB)
Explore Biogen Inc (BIIB) share price insights and analysis for better trading decisions. Stay informed with FP Markets France for expert share price updates.